パフォーマンス向上薬の世界市場レポート2025年

パフォーマンス向上薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.5％で141億6,000万米ドルに成長します。予測期間における主な促進要因としては、活力強化や老化対策製品への投資の増加、疲労や慢性ストレスに関連する症状の急増、新興市場での採用拡大、遺伝子ドーピングや合成生物学の利用拡大、教育や職業環境における認知機能強化への関心の高まりなどが挙げられます。今後予想される顕著な動向としては、医薬品製剤の革新、創薬におけるAIの活用、ハイテクを駆使した個別化サプリメント、遺伝子編集と合成生物学の飛躍的進歩、向知性化合物開発の継続的進展などが挙げられます。

フィットネス活動への関心の高まりは、今後のパフォーマンス向上薬市場の成長を促進すると予想されます。フィットネス活動とは、健康、筋力、柔軟性、全体的な体調を改善または維持するために行われる身体運動や動作を指します。フィットネス活動への関心が高まっているのは、主に健康意識の高まりによるもので、慢性疾患の予防や全体的な健康の維持における身体運動の重要性を認識する個人が増加しているためです。パフォーマンス向上薬は、筋力、持久力、回復力などの身体能力を向上させることにより、筋肉の成長を促進し、疲労を軽減し、より長く、より激しいトレーニングセッションを可能にすることで、フィットネス活動でより大きな成果を上げることをサポートします。例えば、英国を拠点とする健康企業PureGymが2024年11月に発表したレポートによると、2024年には個人の48%が定期的な運動を行っており、これは前年から3%増加しています。したがって、フィットネス活動への関心の高まりがパフォーマンス向上薬市場の成長を牽引しています。

スポーツ参加の急増は、今後パフォーマンス向上薬市場の成長を促進すると予想されます。スポーツ参加とは、個人またはチームの一員として、組織的または非公式な身体活動やゲームに参加する行為を指します。このようなスポーツ参加の増加は、主に、定期的な運動が心臓血管の健康を改善し、精神的な幸福を高め、慢性疾患のリスクを低減することをより多くの人々が認識しているため、身体活動の健康上の利点に対する意識の高まりによるものです。パフォーマンス向上薬は、筋力、持久力、スピード、回復時間などの身体的特性を向上させ、アスリートがより集中的にトレーニングし、疲労を軽減し、身体的制約を克服し、競技中に最高のパフォーマンスを維持できるようにすることで、スポーツ参加を支援します。例えば2024年10月、米国の非営利団体であるスポーツ・フィットネス産業協会（SFIA）によると、2023年のチームスポーツへの参加者は前年比で約800万人増加し、2022年から11％の伸びを示しました。したがって、スポーツ参加者の増加がパフォーマンス向上薬市場の成長を後押ししています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のパフォーマンス向上薬：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のパフォーマンス向上薬市場：成長率分析
• 世界のパフォーマンス向上薬市場の実績：規模と成長, 2019-2024
• 世界のパフォーマンス向上薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界のパフォーマンス向上薬：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界のパフォーマンス向上薬市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 覚醒剤
• アナボリックステロイド
• ペプチドホルモン
• ベータ2作動薬
• その他の製品タイプ
• 世界のパフォーマンス向上薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アスリート
• 学生
• 軍隊
• その他の用途
• 世界のパフォーマンス向上薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オンラインストア
• 薬局
• 専門店
• フィットネスセンター
• 直接販売
• 世界のパフォーマンス向上薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• プロアスリート
• アマチュアアスリート
• ボディビルダー
• フィットネス愛好家
• 慢性疾患の患者
• 世界のパフォーマンス向上薬市場、覚醒剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アンフェタミン
• エフェドリン
• カフェイン
• モダフィニル
• メチルフェニデート
• 世界のパフォーマンス向上薬市場アナボリックステロイドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• テストステロン
• ナンドロロン
• スタノゾロール
• オキサンドロロン
• ボルデノン
• 世界のパフォーマンス向上薬市場ペプチドホルモンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• エリスロポエチン（EPO）
• ヒト成長ホルモン（hGH）
• インスリン様成長因子（IGF-1）
• ゴナドトロピン
• 副腎皮質刺激ホルモン
• 世界のパフォーマンス向上薬市場、β2刺激薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• クレンブテロール
• サルブタモール
• フォルモテロール
• テルブタリン
• 世界のパフォーマンス向上薬市場製品タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 利尿剤
• 麻薬
• カンナビノイド
• 選択的アンドロゲン受容体モジュレーター（SARM）
• 抗エストロゲン

第7章 地域別・国別分析

• 世界のパフォーマンス向上薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のパフォーマンス向上薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• パフォーマンス向上薬市場：競合情勢
• パフォーマンス向上薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline PLC Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Amgen Inc.
• Novo Nordisk A/S
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim
• Organon & Co
• Douglas Laboratories
• Balkan Pharmaceuticals
• Onnit Labs LLC
• Geneza Pharmaceuticals
• Taj Pharmaceuticals
• British Dragon
• Aspen API
• Zhengzhou Pharmaceutical Co.
• Hilma Biocare
• Sciroxx

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• パフォーマンス向上薬市場2029：新たな機会を提供する国
• パフォーマンス向上薬市場2029：新たな機会を提供するセグメント
• パフォーマンス向上薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Performance-enhancing drugs are substances designed to boost physical or mental performance by enhancing strength, endurance, focus, or recovery. These substances are frequently used with the intent of improving athletic output, accelerating progress, and achieving better results from training. Their usage is often linked to a strong ambition for excellence and success in competitive environments.

The primary types of performance-enhancing drugs include stimulants, anabolic steroids, peptide hormones, beta-2 agonists, and others. Stimulants work by activating the central nervous system, resulting in heightened alertness, increased energy levels, and improved physical capabilities. These substances are used in a range of scenarios, such as by athletes, students, military personnel, among others, and are distributed via various channels like online platforms, pharmacies, specialty outlets, gyms, and direct sales. The target end users include professional and amateur athletes, bodybuilders, fitness enthusiasts, and patients with chronic health conditions.

The performance enhancing drugs market research report is one of a series of new reports from The Business Research Company that provides performance enhancing drugs market statistics, including performance enhancing drugs industry global market size, regional shares, competitors with the performance enhancing drugs market share, performance enhancing drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the performance enhancing drugs industry. This performance enhancing drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The performance enhancing drugs market size has grown strongly in recent years. It will grow from $10.79 billion in 2024 to $11.42 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. Growth during the historic period was driven by increased enthusiasm for competitive sports, a heightened focus on body image and physical appearance, broader online accessibility to PEDs, historical use in military and defense contexts, and a rise in off-label usage across general populations.

The performance enhancing drugs market size is expected to see strong growth in the next few years. It will grow to $14.16 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. Key drivers in the forecast period include rising investment in products that enhance vitality and combat aging, a surge in conditions linked to fatigue and chronic stress, expanding adoption in emerging markets, increased utilization of gene doping and synthetic biology, and growing interest in cognitive enhancement within educational and professional environments. Prominent trends anticipated include innovations in pharmaceutical drug formulations, the use of AI in drug discovery, tech-driven personalized supplements, breakthroughs in gene editing and synthetic biology, and continued progress in nootropic compound development.

The rising interest in fitness activities is expected to propel the growth of the performance enhancing drugs market going forward. Fitness activities refer to physical exercises or movements performed to improve or maintain one's health, strength, flexibility, or overall physical condition. The increasing interest in fitness activities is primarily driven by greater health awareness, as more individuals recognize the importance of physical exercise in preventing chronic diseases and maintaining overall well-being. Performance enhancing drugs improve physical capabilities such as strength, endurance, and recovery, thereby supporting individuals in achieving greater results in fitness activities by accelerating muscle growth, reducing fatigue, and enabling longer and more intense training sessions. For instance, in November 2024, according to the report published by PureGym, a UK-based health company, in 2024, 48% of individuals are taking part in regular exercise, which is a 3% increase from the previous year. Therefore, the growing interest in fitness activities is driving the growth of the performance enhancing drugs market.

The surge in sports participation is expected to propel the growth of the performance enhancing drugs market going forward. Sports participation refers to the act of taking part in organized or informal physical activities or games, either individually or as part of a team. This increase in sports participation is primarily due to rising awareness of the health benefits of physical activity, as more people recognize that regular exercise can improve cardiovascular health, boost mental well-being, and reduce the risk of chronic diseases. Performance enhancing drugs aid in sports participation by improving physical attributes such as strength, endurance, speed, and recovery time, allowing athletes to train more intensively, reduce fatigue, overcome physical limitations, and maintain peak performance during competitive events. For instance, in October 2024, according to the Sports & Fitness Industry Association, a US-based non-profit organization, SFIA data indicated that participation in team sports increased by about 8 million people in 2023 compared to the previous year, marking an 11% growth from 2022. Therefore, the increase in sports participation is fueling the growth of the performance enhancing drugs market.

Major companies operating in the performance enhancing drugs market are focusing on developing solutions such as nootropic supplements aimed at enhancing cognitive functions such as memory, focus, and mental clarity. Nootropic supplements refer to substances-natural, synthetic, or a combination-designed to enhance cognitive functions including memory, learning, attention, focus, and mental clarity. For instance, in February 2022, Jones Soda, a US-based beverage company, launched a nootropic supplement beverage formulated to support focus, mental clarity, and brain health. The product is inspired by Mike Tyson's personal journey of healing brain injury and emotional trauma through natural, fungal, and plant-based remedies. The beverage contains a proprietary blend of nootropics and adaptogens, including L-theanine, N-acetyl tyrosine, lion's mane mushroom extract, and essential B vitamins (B3, B5, B6, and B12), along with a small amount of caffeine. This formulation is intended to deliver a clean energy boost and cognitive support without the typical mushroom-based taste. The drink is available in two flavors, Tyson's Punch and Tiger's Blood, both offering fruity, crisp, and flavorful profiles in line with Jones Soda's reputation for craft beverages.

Major players in the performance enhancing drugs market are Pfizer Inc., Bayer AG, Novartis AG, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Organon & Co, Douglas Laboratories, Balkan Pharmaceuticals, Onnit Labs LLC, Geneza Pharmaceuticals, Taj Pharmaceuticals, British Dragon, Aspen API, Zhengzhou Pharmaceutical Co., Hilma Biocare, and Sciroxx.

North America was the largest region in the performance enhancing drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in performance enhancing drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the performance enhancing drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The performance enhancing drugs market consists of sales of clear float performance-enhancing drugs, steroid precursors (prohormones), human growth hormone (hGH), erythropoietin (EPO), and creatine. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Performance Enhancing Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on performance enhancing drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for performance enhancing drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The performance enhancing drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Stimulants; Anabolic Steroids; Peptide Hormones; Beta-2 Agonists; Other Product Types
• 2) By Application: Athletes; Students; Militaries; Other Applications
• 3) By Distribution Channel: Online Stores; Pharmacies; Specialty Stores; Fitness Centers; Direct Sales
• 4) By End User: Professional Athletes; Amateur Athletes; Bodybuilders; Fitness Enthusiasts; Patients With Chronic Illnesses
• Subsegments:
• 1) By Stimulants: Amphetamines; Ephedrine; Caffeine; Modafinil; Methylphenidate
• 2) By Anabolic Steroids: Testosterone; Nandrolone; Stanozolol; Oxandrolone; Boldenone
• 3) By Peptide Hormones: Erythropoietin (EPO); Human Growth Hormone (hGH); Insulin-Like Growth Factor (IGF-1); Gonadotropins; Corticotropins
• 4) By Beta-2 Agonists: Clenbuterol; Salbutamol; Formoterol; Terbutaline
• 5) By Other Product Types: Diuretics; Narcotics; Cannabinoids; Selective Androgen Receptor Modulators (SARMs); Anti-Estrogens
• Companies Mentioned: Pfizer Inc.; Bayer AG; Novartis AG; GlaxoSmithKline PLC; Eli Lilly and Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Performance Enhancing Drugs Market Characteristics

3. Performance Enhancing Drugs Market Trends And Strategies

4. Performance Enhancing Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Performance Enhancing Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Performance Enhancing Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Performance Enhancing Drugs Market Growth Rate Analysis
• 5.4. Global Performance Enhancing Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Performance Enhancing Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Performance Enhancing Drugs Total Addressable Market (TAM)

6. Performance Enhancing Drugs Market Segmentation

• 6.1. Global Performance Enhancing Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Stimulants
• Anabolic Steroids
• Peptide Hormones
• Beta-2 Agonists
• Other Product Types
• 6.2. Global Performance Enhancing Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Athletes
• Students
• Militaries
• Other Applications
• 6.3. Global Performance Enhancing Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Online Stores
• Pharmacies
• Specialty Stores
• Fitness Centers
• Direct Sales
• 6.4. Global Performance Enhancing Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Professional Athletes
• Amateur Athletes
• Bodybuilders
• Fitness Enthusiasts
• Patients With Chronic Illnesses
• 6.5. Global Performance Enhancing Drugs Market, Sub-Segmentation Of Stimulants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Amphetamines
• Ephedrine
• Caffeine
• Modafinil
• Methylphenidate
• 6.6. Global Performance Enhancing Drugs Market, Sub-Segmentation Of Anabolic Steroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Testosterone
• Nandrolone
• Stanozolol
• Oxandrolone
• Boldenone
• 6.7. Global Performance Enhancing Drugs Market, Sub-Segmentation Of Peptide Hormones, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Erythropoietin (EPO)
• Human Growth Hormone (hGH)
• Insulin-Like Growth Factor (IGF-1)
• Gonadotropins
• Corticotropins
• 6.8. Global Performance Enhancing Drugs Market, Sub-Segmentation Of Beta-2 Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clenbuterol
• Salbutamol
• Formoterol
• Terbutaline
• 6.9. Global Performance Enhancing Drugs Market, Sub-Segmentation Of Product Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diuretics
• Narcotics
• Cannabinoids
• Selective Androgen Receptor Modulators (SARMs)
• Anti-Estrogens

7. Performance Enhancing Drugs Market Regional And Country Analysis

• 7.1. Global Performance Enhancing Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Performance Enhancing Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Performance Enhancing Drugs Market

• 8.1. Asia-Pacific Performance Enhancing Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Performance Enhancing Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Performance Enhancing Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Performance Enhancing Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Performance Enhancing Drugs Market

• 9.1. China Performance Enhancing Drugs Market Overview
• 9.2. China Performance Enhancing Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Performance Enhancing Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Performance Enhancing Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Performance Enhancing Drugs Market

• 10.1. India Performance Enhancing Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Performance Enhancing Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Performance Enhancing Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Performance Enhancing Drugs Market

• 11.1. Japan Performance Enhancing Drugs Market Overview
• 11.2. Japan Performance Enhancing Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Performance Enhancing Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Performance Enhancing Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Performance Enhancing Drugs Market

• 12.1. Australia Performance Enhancing Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Performance Enhancing Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Performance Enhancing Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Performance Enhancing Drugs Market

• 13.1. Indonesia Performance Enhancing Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Performance Enhancing Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Performance Enhancing Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Performance Enhancing Drugs Market

• 14.1. South Korea Performance Enhancing Drugs Market Overview
• 14.2. South Korea Performance Enhancing Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Performance Enhancing Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Performance Enhancing Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Performance Enhancing Drugs Market

• 15.1. Western Europe Performance Enhancing Drugs Market Overview
• 15.2. Western Europe Performance Enhancing Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Performance Enhancing Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Performance Enhancing Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Performance Enhancing Drugs Market

• 16.1. UK Performance Enhancing Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Performance Enhancing Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Performance Enhancing Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Performance Enhancing Drugs Market

• 17.1. Germany Performance Enhancing Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Performance Enhancing Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Performance Enhancing Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Performance Enhancing Drugs Market

• 18.1. France Performance Enhancing Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Performance Enhancing Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Performance Enhancing Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Performance Enhancing Drugs Market

• 19.1. Italy Performance Enhancing Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Performance Enhancing Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Performance Enhancing Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Performance Enhancing Drugs Market

• 20.1. Spain Performance Enhancing Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Performance Enhancing Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Performance Enhancing Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Performance Enhancing Drugs Market

• 21.1. Eastern Europe Performance Enhancing Drugs Market Overview
• 21.2. Eastern Europe Performance Enhancing Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Performance Enhancing Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Performance Enhancing Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Performance Enhancing Drugs Market

• 22.1. Russia Performance Enhancing Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Performance Enhancing Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Performance Enhancing Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Performance Enhancing Drugs Market

• 23.1. North America Performance Enhancing Drugs Market Overview
• 23.2. North America Performance Enhancing Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Performance Enhancing Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Performance Enhancing Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Performance Enhancing Drugs Market

• 24.1. USA Performance Enhancing Drugs Market Overview
• 24.2. USA Performance Enhancing Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Performance Enhancing Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Performance Enhancing Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Performance Enhancing Drugs Market

• 25.1. Canada Performance Enhancing Drugs Market Overview
• 25.2. Canada Performance Enhancing Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Performance Enhancing Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Performance Enhancing Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Performance Enhancing Drugs Market

• 26.1. South America Performance Enhancing Drugs Market Overview
• 26.2. South America Performance Enhancing Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Performance Enhancing Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Performance Enhancing Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Performance Enhancing Drugs Market

• 27.1. Brazil Performance Enhancing Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Performance Enhancing Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Performance Enhancing Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Performance Enhancing Drugs Market

• 28.1. Middle East Performance Enhancing Drugs Market Overview
• 28.2. Middle East Performance Enhancing Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Performance Enhancing Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Performance Enhancing Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Performance Enhancing Drugs Market

• 29.1. Africa Performance Enhancing Drugs Market Overview
• 29.2. Africa Performance Enhancing Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Performance Enhancing Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Performance Enhancing Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Performance Enhancing Drugs Market Competitive Landscape And Company Profiles

• 30.1. Performance Enhancing Drugs Market Competitive Landscape
• 30.2. Performance Enhancing Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. GlaxoSmithKline PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

31. Performance Enhancing Drugs Market Other Major And Innovative Companies

• 31.1. Amgen Inc.
• 31.2. Novo Nordisk A/S
• 31.3. Teva Pharmaceutical Industries Ltd.
• 31.4. Boehringer Ingelheim
• 31.5. Organon & Co
• 31.6. Douglas Laboratories
• 31.7. Balkan Pharmaceuticals
• 31.8. Onnit Labs LLC
• 31.9. Geneza Pharmaceuticals
• 31.10. Taj Pharmaceuticals
• 31.11. British Dragon
• 31.12. Aspen API
• 31.13. Zhengzhou Pharmaceutical Co.
• 31.14. Hilma Biocare
• 31.15. Sciroxx

32. Global Performance Enhancing Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Performance Enhancing Drugs Market

34. Recent Developments In The Performance Enhancing Drugs Market

35. Performance Enhancing Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Performance Enhancing Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Performance Enhancing Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Performance Enhancing Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer